Related Experiment Video
Updated: Jul 17, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer
Ling Tong1,2, Xiangling Yu1, Shan Wang1,2
1Human Reproductive and Genetic Center, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China.
Abstract:
Breast cancer has become the most common malignant tumor worldwide. Triple-negative breast cancer (TNBC) is a type of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Compared with other molecular subtypes of breast cancer, TNBC is the most aggressive and highly heterogeneous. TNBC is insensitive to endocrine and anti-HER2 therapy, and chemotherapy is currently the main systemic treatment. With the continuous development of detection techniques and deepening research on TNBC molecular subtypes, drugs targeting immune checkpoints and different targets have emerged, such as atezolizumab, pembrolizumab, poly (ADP-ribose) polymerase (PARP) inhibitors, trophoblast cell-surface antigen 2 (TROP-2), and antibody-drug conjugates. These therapies provide new hope for TNBC treatment. Based on the analysis and classification of TNBC, this article summarizes the immunotherapy, targeted therapy, and new treatment combinations, providing references for the precise treatment of TNBC in the future.
Insights
Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies. Emerging treatments like immunotherapy and antibody-drug conjugates offer new hope for precise TNBC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Breast cancer is the most common malignancy globally.
- Triple-negative breast cancer (TNBC) lacks ER, PR, and HER2 expression, making it aggressive and heterogeneous.
- TNBC is resistant to endocrine and anti-HER2 therapies, with chemotherapy as the primary treatment.
Purpose of the Study:
- To summarize current and emerging treatment strategies for TNBC.
- To provide an overview of immunotherapies, targeted therapies, and combination treatments for TNBC.
- To offer references for precise TNBC treatment based on molecular subtypes.
Main Methods:
- Review of scientific literature on TNBC treatment.
- Analysis and classification of TNBC molecular subtypes.
- Synthesis of data on novel therapeutic agents and approaches.
Main Results:
- Identification of novel therapeutic targets and drugs for TNBC.
- Emergence of immunotherapies (e.g., atezolizumab, pembrolizumab).
- Development of targeted therapies including PARP inhibitors, TROP-2 ADCs, and other conjugates.
Conclusions:
- New therapies, including immunotherapy and targeted agents, offer significant hope for TNBC.
- Precise treatment of TNBC requires understanding its molecular subtypes.
- Combination therapies and novel drug development are crucial for improving TNBC outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:29Modern Molecular Taxonomy